Interferon Beta-1a (IFN-β1-a), an immunomodulatory mediator with antiviral effects, has shown in vivo and in vitro activities especially on coronavirus including SARS-CoV-2. COVID-19 defined as the disease caused by infection with SARS-CoV-2. The virus has been illustrated inhibits the production of IFN-β1-a from inflammatory cells. We conducted a retrospective study of all adult confirmed COVID-19 hospitalized patients who received combination of three doses of 12 million international units of IFN-β1-a and Lopinavir 400 mg and Ritonavir 100 mg every 12 h (case group) for 14 days besides standard care and age- and sex- matched COVID-19 patients with receiving lopinavir/ritonavir (control group) at Masih Daneshvari Hospital as a designated hospital for COVID-19 between Feb 19 and Apr 30, 2020. Multivariate analysis was done to determine the impact of IFN-β1-a on outcome and all-cause mortality. 152 cases in IFN-β1-a group and 304 cases as control group were included. IFN-β1-a group stayed at hospital longer and required noninvasive ventilation more than control group (13 vs. 6 days, p = 0.001) and (34% vs. 24%, p = 0.04), respectively. During treatment, 57 (12.5%) patients died. The death rate in case and control groups was 11% and 13% respectively. In multivariate analysis, not receiving IFN-β1-a (HR 5.12, 95% CI: 2.77–9.45), comorbidity (HR 2.28, 95% CI: 1.13–4.60) and noninvasive ventilation (HR 2.77, 95% CI: 1.56–4.93) remained significantly associated with all-cause mortality. In this study, risk of death decreased by using IFN-β1-a in COVID-19 patients. More clinical study will be necessary to measure efficacy of IFN-β1-a in COVID-19 treatment.

干扰素 Beta-1a (IFN-β1-a) 是一种具有抗病毒作用的免疫调节介质，已显示出体内和体外活性，尤其是对包括 SARS-CoV-2 在内的冠状病毒。COVID-19 定义为由感染 SARS-CoV-2 引起的疾病。该病毒已被证明可抑制炎症细胞产生 IFN-β1-a。我们对所有成人确诊的 COVID-19 住院患者进行了一项回顾性研究，这些患者每 12 小时接受三剂 1200 万国际单位的 IFN-β1-a 和洛匹那韦 400 mg 以及利托那韦 100 mg 的组合（病例组），持续 14 天，此外2020 年 2 月 19 日至 4 月 30 日期间在 Masih Daneshvari 医院作为 COVID-19 指定医院接受洛匹那韦/利托那韦（对照组）的标准护理和年龄和性别匹配的 COVID-19 患者。进行多变量分析以确定 IFN-β1-a 对结果和全因死亡率的影响。纳入IFN-β1-a组152例和对照组304例。IFN-β1-a 组住院时间和无创通气需求分别高于对照组（13 天对 6 天，p = 0.001）和（34% 对 24%，p = 0.04）。治疗期间，57 名 (12.5%) 患者死亡。病例组和对照组的死亡率分别为11%和13%。在多变量分析中，未接受 IFN-β1-a（HR 5.12，95% CI：2.77-9.45）、合并症（HR 2.28，95% CI：1.13-4.60）和无创通气（HR 2.77，95% CI：1.56- 4.93) 仍然与全因死亡率显着相关。在这项研究中，通过在 COVID-19 患者中使用 IFN-β1-a 降低了死亡风险。